Kathryn Kincaide, NP
Family · Lee's Summit, MONPI 1639584790
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 214 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,095 and has fallen 60.9% since, to $428 in 2025. Among family clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 214 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$880
- Boehringer Ingelheim$470
- GSK$460
- Grifols USA, LLC$405
- Sanofi$311
- Regeneron Healthcare Solutions, Inc.$149
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,910100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 45 | $880 |
| Boehringer Ingelheim | 27 | $470 |
| GSK | 33 | $460 |
| Grifols USA, LLC | 24 | $405 |
| Sanofi | 10 | $311 |
| Regeneron Healthcare Solutions, Inc. | 7 | $149 |
| Amgen | 7 | $139 |
| United Therapeutics Corporation | 7 | $126 |
| Genentech USA, Inc. | 8 | $116 |
| Merck | 6 | $115 |
| Mylan Specialty L.p. | 6 | $109 |
| Jazz Pharmaceuticals Inc. | 5 | $93 |
| Harmony Biosciences LLC | 3 | $74 |
| Inogen, Inc. | 4 | $60 |
| Novartis | 3 | $52 |
| AbbVie | 2 | $47 |
| Baxter Healthcare | 2 | $39 |
| Inspire Medical Systems, Inc. | 2 | $35 |
| Insmed, Inc. | 2 | $34 |
| Electromed, Inc. | 2 | $31 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Shionogi Inc | 1 | $21 |
| Philips North America LLC | 1 | $20 |
| Verona Pharma, Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$3,910 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 401 | $332,590 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 241 | $170,846 |
| XolairOmalizumab | 39 | $151,442 |
| NucalaMepolizumab | 29 | $106,746 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 121 | $105,562 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $95,175 |
| Spiriva RespimatTiotropium Bromide | 94 | $74,126 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 130 | $68,818 |
| Breo ElliptaFluticasone/Vilanterol | 135 | $61,685 |
| SymbicortBudesonide/Formoterol Fumarate | 129 | $45,562 |
| Spiriva HandihalerTiotropium Bromide | 53 | $37,223 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 100 | $17,514 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 659 | $16,321 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 86 | $16,167 |
| XareltoRivaroxaban | 13 | $11,318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $460 | $585,379740 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $880 | $216,408370 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $470 | $179,689215 claims |
| Grifols USA, LLCProlastin C | $405 | $95,17511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.
Other family in Lee's Summit
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
- Jennifer GriggColumbia$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.